Fresenius SE & Co. KGaA (DE:FRE)
XETRA:FRE
Want to see DE:FRE full AI Analyst Report?
FRE Stock Chart & Stats
€44.62
€0.28(0.81%)
At close: 4:00 PM EST
€44.62
€0.28(0.81%)
Day’s Range― - ―
52-Week Range€38.16 - €52.96
Previous CloseN/A
Volume90.82K
Average Volume (3M)750.62K
Market Cap
€21.63B
Enterprise Value€32.18B
Total Cash (Recent Filing)€2.06B
Total Debt (Recent Filing)€11.90B
Price to Earnings (P/E)14.3
Beta0.83
Next Earnings
Aug 05, 2026EPS Estimate
0.88Next Dividend Ex-DateN/A
Dividend Yield2.05%
Share Statistics
EPS (TTM)2.66
Shares Outstanding563,237,300
10 Day Avg. Volume787,875
30 Day Avg. Volume750,621
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€54.96Price Target Upside23.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)3.55
Revenue Forecast (FY)€23.63B
Bulls Say, Bears Say
Bulls Say
Margin Recovery And ProfitabilityMargins and net income recovery from the 2023 loss indicate the business regained operational control and pricing/volume balance. Higher margins increase durable internal cash generation, support reinvestment into core segments, and reduce reliance on external financing over the next several quarters.
Strong Free Cash Flow ReboundA durable FCF rebound and healthy cash conversion create flexibility to pay down debt, fund capital expenditure in Kabi and FMC, sustain dividends or strategic investments. Consistent positive operating cash flow underpins the group's ability to weather reimbursement cycles and support long-term operations.
Improved Leverage And Balance-sheet FlexibilityMaterial reduction in leverage versus earlier years lowers refinancing and interest risks and boosts financial flexibility. A stronger equity base and lower debt-to-equity enhance capacity for strategic moves, capital allocation, and resilience to cyclical stress across healthcare services and product businesses.
Bears Say
Choppy Multi-year Revenue TrajectoryPersistent revenue volatility undermines predictability for cash flows and investment planning. Structural or market headwinds (tenders, reimbursements, pandemic-related shifts) may limit sustainable topline expansion and make medium-term capacity utilization and margin forecasts less reliable.
High Absolute Debt StockEven with improved ratios, a large nominal debt burden increases vulnerability to slower revenue or margin compression, raises interest expense sensitivity to rate moves, and constrains capital allocation choices if cash generation weakens in adverse scenarios.
Moderate Return On EquitySub‑10% ROE suggests the group generates only modest shareholder returns relative to capital employed. This limits room for rapid equity value creation and may reflect structural margin limitations in clinical products and services, or competitive pressure in core markets over the medium term.
Fresenius SE & Co. KGaA News
FRE FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest stock price was €38.16 and its highest was €52.96 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is €21.63B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Aug 05, 2026 which is in 77 days.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Fresenius SE & Co. KGaA released its earnings results on May 06, 2026. The company reported €0.82 earnings per share for the quarter, missing the consensus estimate of €0.875 by -€0.055.
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA pays a Annually dividend of €1 which represents an annual dividend yield of 2.05%. See more information on Fresenius SE & Co. KGaA dividends here
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.88.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Fresenius SE & Co. KGaA reported an EPS of €0.82 in its last earnings report, missing expectations of €0.875. Following the earnings report the stock price went up 1.141%.
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€54.96 (23.16% Upside)
€54.96 (23.16% Upside)
Insider Transactions
Bought Shares
Worth €597.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.67%
12-Months-Change
Fundamentals
Return on Equity
7.76%
Trailing 12-Months
Asset Growth
-1.94%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
FRE Stock 12 Month Forecast
Average Price Target
€54.96
▲(23.16% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―
Options Prices
Currently, No data available
---